Rosacea 2009. New advances in pathophysiology, clinical staging and therapeutic strategies;Rosazea 2009. Neue Erkenntnisse zur Pathophysiologie, klinische Manifestationsformen und Therapiestrategien

Hautarzt

Volumn 60, Issue 12, 2009, Pages 999-1009

  Sobottka, A ^a   Lehmann, P ^a  

^a HELIOS KLINIKUM WUPPERTAL   (Germany)

Author keywords

Clinical subtypes; Immunity; Pathophysiology; Rosacea; Therapeutic options

Indexed keywords

AZELAIC ACID; AZITHROMYCIN; CALCINEURIN INHIBITOR; CLINDAMYCIN; DISULFIRAM; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; OXYTETRACYCLINE; PERMETHRIN; PIMECROLIMUS; PLACEBO; PREDNISOLONE; ROXITHROMYCIN; SULFUR; TACROLIMUS; TETRACYCLINE;

DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; HUMAN; INNATE IMMUNITY; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MUSCLE CRAMP; NEUROPATHY; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; REVIEW; ROSACEA; SIDE EFFECT; SKIN ABRASION; SKIN COLOR; TELANGIECTASIA;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; ISOTRETINOIN; MALE; MICE; NIACINAMIDE; RHINOPHYMA; RISK FACTORS; ROSACEA; SKIN; TELANGIECTASIS; ULTRAVIOLET RAYS;

EID: 73949106230     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-009-1825-y     Document Type: Review

References (63)

1. Schaefer I et al (2008) Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 217(2):169-172
2. Berg M, Liden S (1989) An epidemiological study of rosacea. Acta Derm Venereol 69(5):419-423
3. Yazici AC et al (2006) GSTM1 and GSTT1 null genotypes as possible heritable factors of rosacea. Photodermatol Photoimmunol Photomed 22(4):208-210
4. Wilkin JK (1994) Rosacea. Pathophysiology and treatment. Arch Dermatol 130(3):359-362
5. Lehmann P (2005) Rosazea: Epidemiologie, Pathogenese, Klinik und Therapie. Hautarzt 56(9):871-885
6. Brinnel H et al (1989) Rosacea: disturbed defense against brain overheating. Arch Dermatol Res 281(1):66-72
7. Nagasaka T et al (1998) Selective brain cooling in hyperthermia: the mechanisms and medical implications. Med Hypotheses 50(3):203-211
8. Smith JR et al (2007) Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol 91(2):226-229
9. Aroni K et al (2008) A study of the pathogenesis of Rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res 300(3):125-131
10. Roihu T, Kariniemi AL (1998) Demodex mites in acne rosacea. J Cutan Pathol 25(10):550-552
11. Forton F, Seys B (1993) Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 128(6):650-659
12. Lacey N et al (2007) Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol 157(3):474-481
13. Wilkin J et al (2002) Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 46(4):584-587
14. Yamasaki K et al (2007) Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13(8):975-980
15. Yamasaki K, Gallo RL (2009) The molecular pathology of rosacea. J Dermatol Sci 55(2):77-81
16. Salamon M et al (2008) Concentration of selected cytokines in serum of patients with acne rosacea. Przegl Lek 65(9):371-374
17. Jones D (2004) Reactive oxygen species and rosacea. Cutis 74 (Suppl 3):17-20, 32-34
18. Miyachi Y (2001) Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther 18(6):237-243
19. Tisma VS et al (2009) Oxidative stress and ferritin expression in the skin of patients with rosacea. J Am Acad Dermatol 60(2):270-276
20. Lehmann P (2007) Rosazea: Epidemiologie, Pathogenese, Klinik und Therapie. Dtschrztebl 104(24):A-1741/B-1536/C-1475(104(24)
21. Lehmann P, Arens A (2000) Rosacea fulminans. In: Plettenberg A, Meigel WN, Moll I (Hrsg) Dermatologie an der Schwelle zum neuen Jahrtausend. Springer, Berlin Heidelberg New York Tokyo, S 257-259
22. Wilkin J et al (2004) Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 50(6):907-912
23. Plewig GK, Kligman AM (2000) Acne and rosacea, Vol. 1, 3rd edn. Springer, Berlin Heidelberg New York Tokyo, p 744
24. Payne WG et al (2006) Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma. Ann Plast Surg 56(3):301-305
25. Powell F (2009) Rosacea - diagnosis and management, Vol. 1. Informa Healthcare USA, Inc., p 140
26. Nagasaka T et al (2008) Persistent lymphoedema in Morbihan disease: formation of perilymphatic epithelioid cell granulomas as a possible pathogenesis. Clin Exp Dermatol 33(6):764-767
27. Jayawant SS et al (2008) Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea. J Dermatolog Treat 19(5):267-273
28. Mostafa FF et al (2009) Comparative study of some treatment modalities of rosacea. J Eur Acad Dermatol Venereol 23(1):22-28
29. Thiboutot DM et al (2008) Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol 7(6):541-546
30. Lehmann P (2003) Klinische Studien zur topischen Therapie mit Metronidazol bei Rosazea. In: Schäfer H (Hrsg) Rosazea-Klinik und aktuelle Therapie. Georg Thieme, Stuttgart, S 41-50
31. van Zuuren EJ et al (2004) Interventions for rosacea. Cochrane Database Syst Rev 2004(1):CD003262
32. Altinyazar HC et al (2005) Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 44(3):252-255
33. Czernielewski J, Liu Y (2004) Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea. Arch Dermatol 140(10):1282-1283; author reply 1283
34. Bleicher PA, Charles JH, Sober AJ (1987) Topical metronidazole therapy for rosacea. Arch Dermatol 123(5):609-614
35. Crawford KM, Russ B, Bostrom P (2005) Pimecrolimus for treatment of acne rosacea. Skinmed 4(3):147-150
36. Cunha PR, Rossi AB (2006) Pimecrolimus cream 1% is effective in a case of granulomatous rosacea. Acta Derm Venereol 86(1):71-72
37. Kheirkhah A et al (2007) Corneal manifestations of ocular demodex infestation. Am J Ophthalmol 143(5):743-749
38. Schöfer H (2003) Rosazea: Klinik und aktuelle Therapie. Georg Thieme, Stuttgart New York
39. Sharquie KE, Najim RA, Al-Salman HN (2006) Oral zinc sulfate in the treatment of rosacea: a double-blind, placebo-controlled study. Int J Dermatol 45(7):857-861
40. Erdogan FG et al (1998) Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 134(7):884-885
41. Dahl MV et al (1998) Topical metronidazole maintains remissions of rosacea. Arch Dermatol 134(6):679-683
42. Sanchez J et al (2005) A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol 53(5):791-797
43. Fowler JF Jr (2007) Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 6(6):641-645
44. Bender A et al (2008) Tetracycline suppresses ATP gamma S-induced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells. Exp Dermatol 17(9):752-760
45. Del Rosso JQ et al (2007) Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 56(5):791-802
46. Del Rosso JQ, Schlessinger J, Werschler P (2008) Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 7(6):573-576
47. Berman B, Perez OA, Zell D (2004) Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc) 43(1):27-34
48. Berman B, Zell D (2005) Subantimicrobial dose doxycycline: a unique treatment for rosacea. Cutis 75 (Suppl 4):19-24
49. Theobald K, Bradshaw M, Leyden J (2007) Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed 6(5):221-226
50. Wise RD (2007) Submicrobial doxycycline and rosacea. Compr Ther 33(2):78-81
51. Bakar O et al (2009) Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol 23(5):544-549
52. Bakar O et al (2007) The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol 32(2):197-200
53. Maatta M et al (2006) Tear fluid levels of MMP-8 are elevated in ocular rosacea--treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol 244(8):957-962
54. Bernstein EF, Kligman A (2008) Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser. Lasers Surg Med 40(4):233-239
55. Cravo M et al (2009) Combined carbon dioxide laser and bipolar electrocoagulation: another option to treat rhinophyma. J Dermatolog Treat 20(3):146-148
56. Bryld LE, Jemec GB (2007) Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venereol 21(9):1199-1202
57. Katz B, Patel V (2006) Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea. J Drugs Dermatol 5 (Suppl 2):6-8
58. Neuhaus IM, Zane LT, Tope WD (2009) Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg 35(6):920-928
59. Papageorgiou P et al (2008) Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol 159(3):628-632
60. Salamon M et al (2008) Quality of life in patients with rosacea. Przegl Lek 65(9):385-389
61. Chodkiewicz J et al (2007) Psychosocial impact of rosacea. Przegl Lek 64(12):997-1001
62. Gupta MA et al (2005) Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey - Outpatient Department Data collected by the U.S. National Center for Health Statistics from 1995 to 2002. Br J Dermatol 153(6):1176-1181
63. Gollnick H et al (2009) Therapie der Rosazea mit Isotretinoin. Eine Multicenter Studie. JDDG (in press)